Outcomes with first-line (1L) ribociclib (RIB) plus endocrine therapy (ET) vs physician's choice combination chemotherapy (combo CT) by age in pre/perimenopausal patients (pts) with aggressive HR+/HER22-advanced breast cancer (ABC): A subgroup analysis of the RIGHT Choice trial.
JOURNAL OF CLINICAL ONCOLOGY(2023)
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined